Abstract
Since 1990, aerosol interleukin (IL)-2 has been used to treat pulmonary metastatic renal cell carcinoma (pmRCC). Inhalation therapy deposits a drug into the airways to achieve a high, local, clinical effect while avoiding serious systemic side effects. We report three studies to describe safety and efficacy of aerosol IL-2 in patients with pmRCC. In a multicenter study, 24 patients received exclusive inhalation (study I) of natural IL-2 (three dose levels, 48 weeks) and response and toxicity were evaluated. The survival of high-risk patients (study II) with mainly inhaled IL-2 (n=94) was compared with that of patients receiving systemic IL-2 (n=103). In ten patients we analyzed in detail lung function and markers of airway inflammation before and during inhalational IL-2 therapy (study III). Study I: The response of exclusive inhalation was 33.3% at 3 months and 16.7% at 6 months. Treatment was well tolerated, cough being the most frequent adverse event. Study II: The probabilities of survival at 5 years were 21% for the inhalational group and 0% for the systemic group. Study III: Inhaled IL-2 induced a moderate decline of forced expiratory volume (FEV), while exhaled nitric oxide (NO) and sputum eosinophils rose accompanied by moderate cough and dyspnea. In conclusion, inhalational IL-2 combines good efficacy and improves tolerability. This is especially important for patients who are not able to benefit from systemic IL-2 therapy. Whether the local eosinophilic response additionally supports the antitumor effect remains a challenging question.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310–7313
Cotran RS, Pober JS, Gimbrone MA, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT (1988) Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 140:1883–1888
Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R, Franks CR (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Annals Oncol 3:475–480
Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A, Heinzer H, Heynemann H, Hoffmann L, Hofmann R, Huland H, Kämpfer I, Kindler M, Kirchner H, Mehlhorn G, Moniak Th, Rebmann U, Roigas J, Schneider Th, Schnorr D, Schmitz H-J, Wenisch R, Varga Z, Vinke J (2003) Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol 49:183–190
Loppow D, Huland E, Heinzer H, Grönke L, Gercken G, Magnussen H, Jörres RA (2004) Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation. Resp Med (in press)
Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol 21:3127–3132
American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679
Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928–1935
Motzer RJ, Mazumdar M, Bacik J (1999) Survival and Prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17:2530–2540
Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310–1314
Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198–1220
Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368–1375
Clark JI, Gaynor ER, Martone B Budds SC, Manjunath R, Waters WB, Sosman JA (1999) Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin Cancer Res 5:2374–2380
Heinzer H, Mir TS, Huland E, Huland H (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 17:3612–3620
http://www.emea.eu.int/pdfs/human/comp/opinion/122803en.pdf. Cited on 18.8.2003
Lorenz J, Wilhelm K, Kessler M, et al (1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 2:1115–1122
Zissel G, Aulitzky WE, Lorenz J, Huber C, Müller-Quernheim J (1996) Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol Immunother 42:122–126
Gaede KI, Zissel G, Schwulera U, Struff WG, Lorenz J, Aulitzky WE, Zipfel P, Schrum S, Schlaak M, Huber C, Müller-Quernheim J (1997) Spontaneous and interleukin-2-modulated cytokine release by bronchoalveolar cells in pulmonary malignancy. Eur Cytokine Netw 8:395–400
Acknowledgements
Chiron BV is acknowledged for providing support with the statistical analysis in study II.
Conflict of interest:
No information supplied
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huland, E., Heinzer, H., Jörres, R.A. et al. Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy. Urologe 43 (Suppl 3), 140–144 (2004). https://doi.org/10.1007/s00120-004-0606-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-004-0606-6